International Prevention Research Institute, Lyon, France.
J Clin Endocrinol Metab. 2012 Aug;97(8):2606-13. doi: 10.1210/jc.2012-1238. Epub 2012 Jun 14.
Few studies in subjects over 50 yr of age have evaluated the influence of variable doses of vitamin D supplementation on serum 25-hydroxyvitamin D levels.
We performed a meta-analysis of changes in circulating 25-hydroxyvitamin D level associated with vitamin D supplementation in Caucasian subjects over 50 yr old.
We conducted a systematic search in literature databases and in references of past reviews.
Randomized placebo or open-label trials that evaluated the influence of vitamin D supplementation on clinical outcomes were included in the study.
We reviewed trial characteristics and serum 25-hydroxyvitamin D concentrations at baseline and during the trial.
Seventy-six trials published from 1984 to March 2011 included 6207 subjects allocated to 101 intervention groups that tested supplement doses ranging from 5 to 250 μg/d (median, 20 μg/d). For similar doses, trials could obtain increases in 25-hydroxyvitamin D three to four times lower than other trials. A meta-regression showed that in the absence of concomitant use of calcium supplements, the average increase in serum 25-hydroxyvitamin D concentrations was 0.78 ng/ml (1.95 nmol/liter) per microgram of vitamin D3 supplement per day. Compared to the vitamin D3, the vitamin D2 was associated with significantly lower increases (P = 0.03). Concomitant use of calcium supplementation and high 25-hydroxyvitamin D concentration at baseline was nonsignificantly associated with lower increases in 25-hydroxyvitamin D concentrations.
Dietary recommendations and randomized trials on vitamin D supplementation should evaluate whether increases in circulating 25-hydroxyvitamin D levels match expectations--for instance, the average increases obtained by trials on vitamin D3 without concomitant calcium supplements.
在 50 岁以上的人群中,很少有研究评估维生素 D 补充剂的不同剂量对血清 25-羟维生素 D 水平的影响。
我们对 50 岁以上白种人进行了一项荟萃分析,以评估维生素 D 补充对循环 25-羟维生素 D 水平的影响。
我们在文献数据库和过去综述的参考文献中进行了系统搜索。
纳入的研究为评估维生素 D 补充对临床结局影响的随机安慰剂或开放标签试验。
我们回顾了试验特征和试验开始时及期间的血清 25-羟维生素 D 浓度。
1984 年至 2011 年 3 月发表的 76 项试验纳入 6207 名受试者,他们被分配到 101 个干预组,这些组测试的补充剂量范围为 5 至 250μg/d(中位数为 20μg/d)。对于类似的剂量,试验获得的 25-羟维生素 D 增加量比其他试验低 3 至 4 倍。一项荟萃回归分析显示,在没有同时使用钙补充剂的情况下,血清 25-羟维生素 D 浓度的平均增加量为每天每微克维生素 D3 补充剂增加 0.78ng/ml(1.95nmol/l)。与维生素 D3 相比,维生素 D2 与较低的增加量显著相关(P=0.03)。同时使用钙补充剂和较高的基线 25-羟维生素 D 浓度与 25-羟维生素 D 浓度的增加量较低无关。
膳食推荐和维生素 D 补充的随机试验应评估循环 25-羟维生素 D 水平的增加是否符合预期,例如,在没有同时使用钙补充剂的情况下,维生素 D3 试验获得的平均增加量。